

Venture Capital Fund Commitment

# Aisling Capital III, L.P.

March 6, 2008

Charles J. Spiller, Director of Private Markets and Real Estate

# Aisling Capital III, L.P. – Venture Capital

Overview:


- Fund size is \$650 million
- Investments in products, technologies and businesses that advance health.
- Some investments may be made outside the U.S.

Fund Strategy:

- Investments will be made in companies developing pharmaceutical, biopharmaceutical, and medical products, drug development, manufacturing and other healthcare services.
- Strategy will: (i) identify outstanding products and undervalued businesses; (ii) capitalize on market inefficiencies; (iii) manage investment risk; and (iv) build sustainable companies.
- Pennsylvania Presence 3 Pennsylvania investments:


Auxillium Pharmaceuticals – Hormone replacement therapy CardioKine – Drugs to treat congestive heart failure Topaz – Treatment of head lice





6 **Private & Confidential** 

**AISLIN G CAPITAL** 



8 **Private & Confidential** 

**AISLING CAPITAL** 

# Aisling Capital III, L.P. – Venture Capital

Investment Team:

- The principals have extensive experience as active members of boards of directors, as well as supervisory management experience.
- As board members of the Partnership's portfolio companies, the Principals will assist in establishing long term strategic direction, identifying and evaluating acquisitions, and new business opportunities.

Performance:

- Fund I: \$449M in committed capital, \$388M invested capital, 25 investments to date, 2.3X investment multiple, net IRR 29.1%.
- Fund II: \$550M in committed capital, the IRR of this 2006 vintage year fund is not yet meaningful.

## Aisling Capital III, L.P. – Venture Capital

#### Market Opportunity:

- Trends in the healthcare industry are creating attractive opportunities for venture capital investments.
- Aisling III gives PSERS additional exposure in this space.

# History with PSERS:

 This would be PSERS third fund with Aisling (Perseus-Soros BioPharmaceutical Fund – 2001, and Aisling Capital II – 2006).

### Recommendation:

• Staff, together with Portfolio Advisors, recommends that the Board invest an amount equal to 25 percent of the committed capital, but not to exceed \$100 million plus reasonable normal investment expenses.